



Teniposide

Catalog No: tcsc1366

Observed Molecular Weight:

656.65

Available Sizes		
Size: 25mg		
Size: 50mg		
Size: 100mg		
Size: 200mg		
Specifications		
CAS No: 29767-20-2		
Formula: C ₃₂ H ₃₂ O ₁₃ S		
Pathway: Cell Cycle/DNA Damage		
Target: Topoisomerase		
Purity / Grade: >98%		
Solubility: DMSO : ≥ 30 mg/mL (45.69 mM)		
Alternative Names: VM26		



Product Description

Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.

IC50 & Target: Topoisomerase II^[2]

In Vitro: Teniposide is a topoisomerase II inhibitor. Teniposide (VM-26, 0.15-45 mg/L) inhibits the proliferation of Tca8113 cells in a dose-dependent manner, with an IC $_{50}$ of 0.35 mg/L. Teniposide (5 mg/L) induces apoptosis of Tca8113 cells. Teniposide (5.0 mg/L) causes cell arrested at G2/M phase in Tca8113 cells^[2]. Teniposide is active on primary cultured glioma cells from patients, when the level of miR-181b is high in the cells, with an IC $_{50}$ of 1.3 \pm 0.34 μ g/mL. Cells treated with teniposide with low MDM2 have decreased viability compared with control cells, and the IC $_{50}$ decreases from 5.86 \pm 0.36 μ g/mL to 2.90 \pm 0.35 μ g/mL upon MDM2 suppression. Teniposide also inhibits the viability of glioma cell with high level of miR-181b, through mediation of MDM2^[3].

In Vivo: Teniposide (0.5 mg/kg, i.p.) significantly increases micronucleated polychromatic erythrocyte (MNPCE) frequencies, which is directly related to bone marrow toxicity as significant suppression of bone marrow is noted. Teniposide (24 mg/kg, i.p.) markedly decreases the frequencies of BrdU-labelled sperm. Teniposide (12, 24 mg/kg, i.p.) also dramatically induces disomic sperm in the germ cell of male mice^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!